The smallest Cas13 family protein, CasRx, has a high cleavage activity and targeting specificity, offering attractive opportunity for therapeutic applications. Here we report that delivery of CasRx by adeno-associated virus via intravitreal injection could efficiently knockdown Vegfa transcripts and significantly reduce the area of laser-induced choroidal neovascularization in a mouse model of age-related macular degeneration.
Thus, RNA-targeting CRISPR system could be used for in vivo gene therapy.
Main
Age-related macular degeneration (AMD), characterized by the development of choroidal neovascularization (CNV), is a leading cause of vision deterioration in adults over age 50 1 . An angiogenic growth factor vascular endothelial growth factor A (VEGFA) plays a crucial role in CNV pathogenesis and anti-VEGFA therapy using humanized antibodies has been widely used in treating AMD, with the therapeutic effects maintained by regular injections of antibodies 2, 3 . Two recent studies showed that in a mouse model of AMD that permanent Vegfa gene disruption could be induced by SpCas9 or LbCpf1 editing 4, 5 . However, risks associated with permanent DNA modifications, including unwanted off-target and on-target effects, need to be considered 6, 7 .
The Cas13 protein family was recently shown to be a programmable RNAtargeting CRISPR system [8] [9] [10] [11] [12] [13] , which could mediated RNA knockdown with high efficiency and specificity relative to other existing RNA interference approaches 8, 9, 12 . Several Cas13 proteins have been identified, among which RfxCas13d (CasRx) has the smallest size and highest RNase activity 12 . Here, we examine the potential application of CasRx system for in vivo gene therapy, using a laser-induced mouse model of AMD. Our results show that adeno-associated viral (AAV)-delivered CasRx could knockdown Vegfa transcripts efficiently, resulting in the significant reduction of CNV area in this AMD model.
We first identified two CasRx targeting sites that are conserved in the human and mouse Vegfa gene. To achieve efficient Vegfa mRNA knockdown, two guide RNAs (gRNAs) targeting these two sites respectively were designed ( Fig. 1a ).
We found that transient transfection of vectors expressing CasRx and the gRNA resulted in marked reduction of the Vegfa mRNA level in cultured human 293T cells (12+/-3.5%, s.e.m.) and mouse N2a cells (29.5 +/-8.4%, s.e.m.) within two days, as compared to cells transfected with the control vector ( Fig. 1b, c) . The VEGFA protein levels were also significantly reduced in mouse N2a cells ( Fig.   1d ). To determine targeting specificity of CasRx, we performed transcriptomewide RNA-seq analysis. Besides Vegfa, the expression levels of many other genes were changed and more than half of top-ranked genes with altered expression were related with Vegfa according to previous studies. Fig. 1 and Supplementary Table 1 ). To investigate the knockdown efficiency of CasRx in the normal mouse retina, we intravitreally injected AAVs encoding CasRx and a dual-gRNA array targeting Vegfa (referred as AAV-CasRx-Vegfa). Three weeks after injection, choroid-retinal pigment epithelial (RPE) tissue complex was isolated for qPCR analysis (Fig. 1e,f) . We observed the expression of AAV-CasRx-Vegfa ( Fig. 1g ) and found that Vegfa transcripts in the treated eye were potently suppressed (65.4 +/-8.7%, s.e.m), as compared to those in the contralateral eye injected with PBS ( Fig. 1h ).
(Supplementary
We next created the AMD mice by inducing CNV in both eyes by laser irradiation ( Supplementary Fig. 2a ,b, also see Methods). To investigate the potential usefulness of mRNA knockdown approach for treating AMD, we injected AAV-CasRx-Vegfa into one eye of the mouse, and PBS in the other eye as control (Fig 1f. Induction of CNV was performed in both eyes three weeks later. After laser burn, we confirmed successful infection of AAV-CasRx-Vegfa ( Supplementary Fig. 3a ). Furthermore, we found that the levels of Vegfa mRNA and VEGFA protein were significantly lower in the AAV-injected eye as compared that those in the contralateral PBS-injected eye (mRNA, 22.7 +/-1.8% s.e.m., p = 0.002; protein, 68.2 +/-8.7%, s.e.m., p = 0.019; unpaired t-test) ( Fig. 1i ,j). Thus, intravitreal injection of the Vegfa mRNA-targeting AAV was efficient to knockdown VEGFA expression in the injected eye. The therapeutic effect of this CasRX approach was assessed by quantifying the CNV area 7 days after laser treatment. Our results showed that Vegfa-targeting AAV markedly reduced the area of CNV at two different levels of laser irradiation, as compared to the control eyes injected with PBS ( Fig. 1k ,l and Supplementary Fig. 3b and 4a,b. 180 mW, 66 +/-7.8%, s.e.m., n = 6 mice, p = 0.004; 240 mW, 36.5 +/-6.9%, s.e.m., n = 4 mice, p = 0.002; unpaired t-test). Reduction of CNV was also confirmed by injecting AAV-CasRx-Vegfa into one eye, and AAV-CasRx with no gRNA into the other eye as control ( Fig. 1m and Supplementary Fig. 4c ). To evaluate the potential toxicity of AAV-CasRx-Vegfa-mediated gene knockdown, we performed electroretinography (ERG) recording in mice at one and two months after the subretinal injection. Our results showed that there is no significant change in the responses in mice injected with AAV-CasRx-Vegfa compared to that in mice injected with PBS ( Supplementary Fig. 5a,b ). In addition, we examined the expression level of opsin in the retina at around 1 month after AAV injection. We found that injection of AAV-CasRx-Vegfa did not affect the opsin-positive areas ( Supplementary Fig. 5c ). Together, these results suggest that AAV-CasRxmediated Vegfa knockdown is a safe way to treat AMD. 
Laser-induced CNV model, CNV staining and ERG
At 2-3 weeks after AAV injection, mice were used for laser burn. CNV models were induced as previously described 3 . In brief, mice were anesthetized and pupils were dilated with dilating eye drops to enlarge the pupil size. Laser photocoagulation was performed using NOVUS Spectra (LUMENIS). The laser parameters used in this study were: 532 nm wave length, 70 ms exposure time, 240 mW power (otherwise stated) and 50 μm spot size. 4 laser burns (30 laser burns for ELISA) around the optic disc were induced. Mice with vitreous hemorrhage were excluded in the study. 3 days after laser induction, mice were perfused with saline and RPE complexes were dissociated for ELISA analysis (qPCR was performed 7 days after laser burn). CNV analysis was conducted 7 days later after laser burn. Mice were perfused with PFA and the eyes were then fixed with PFA for 2 hours. The retina was removed from the eyes, and only RPE/choroid/scleral complex was stained with isolectin-B4 (IB4, 10μg/ml, I21413, Life Technologies) overnight. RPE complexes were flat-mounted and visualized with microscope (VS120 Olympus). Only eyes with successful AAV-CasRx-Vegfa infection were included for quantification. After obtaining CNV images, DNA was extracted from the RPE complex, the copy number of CasRx was evaluated by qPCR. The area of CNV was quantified using ImageJ software by a blind observer. ERG was performed as previously described 4 . Randomization was used in all experiments and no statistical methods were used to pre-determine sample sizes but our sample sizes are similar to those reported in previous publications 5 . VEGFA protein levels were quantified by ELISA 3 days after laser burn. CasRx and Vegfa mRNA levels as well as the area of CNV were measured 7 days after laser burn. (g) CasRx mRNA levels without laser burn, 21 days after AAV injection (n = 3 mice). (h,i) Vegfa mRNA levels before or 7 days after laser burn (Before laser burn: n = 6 mice, p = 0.002, t = 4.059; after laser burn: n = 3 mice, p = 0.002, t = 7.583 ). (j) VEGFA protein levels 3 days after CNV induction (n = 5 mice, p = 0.019, t = 2.928). (PBS + AAV-CasRx-Vegfa: n = 4 mice, p = 0.002, t = 3.39; AAV-CasRx + AAV-CasRx-Vegfa: n = 4 mice, p = 0.0002, t = 4.292). All values are presented as
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